You are here: Home TIRCON Partners TUM-MED

Klinikum rechts der Isar - Technische Universität München

Partner Profile

The Technische Universität München (TUM) has earned a high international reputation that is apparent from research collaborations with more than 140 partner Universities, and its involvement in about 150 FP6 and currently (February 2010) more than 120 FP7 projects. Klinikum rechts der Isar (TUM-MED) is the university hospital of TUM. It is a renowned center for patient care, medical research, and teaching of medicine. It is treating some 40,000 in-house patients and 170,000 out-patients yearly. 

The TUM-MED Institute of Human Genetics (head: Prof. Thomas Meitinger) with its joint institute at Helmholtz Zentrum München provides a powerful infrastructure for genomic research including platforms for next generation sequencing (HighSeq2000), genome wide analysis, metabolomics and computing infrastructure offering a wide range of technologies for systematic molecular research in human populations and model organisms. The institute has long-term experience with disease based biobanking. The Munich group is funded by research grants from The German Research Foundation, the German Research Ministry and the EU, including a Medical System Biology project and a German network for rare mitochondrial disorders, both coordinated by T. Meitinger. The Mitochondrial Disorder Group (head Dr. Holger Prokisch) explores genetic variation in both rare and common disorders with a functional focus on mitochondria-related disease mechanisms.


Klaus A. Kuhn, FACMI, is Full Professor of Medical Informatics at TUM and Director of the Institute of Med. Biometry and Epidemiology at TUM-MED. He is a faculty member of both the medical and the computer science faculty at TUM, a Fellow of the American College of Med. Informatics, and Vice President of the German Assoc. for Med. Informatics, Biometry, and Epidemiology.  He is leading the projects “Data Integration System” and “IT for Biobanking” in the Munich Biotech Cluster M4 which receives significant funding as part of the Federal Government’s High-Tech Strategy.

Main tasks in the consortium

• Leader in WP2 (Biomaterial bank)
• Partner in WP1, WP3, WP4, WP6